Loxapine inhalation - Alexza Pharmaceuticals

Drug Profile

Loxapine inhalation - Alexza Pharmaceuticals

Alternative Names: Adasuve; ALXZ-004; AZ-004; Staccato Loxapine

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alexza Pharmaceuticals
  • Developer Alexza Pharmaceuticals; AOP Orphan Pharmaceuticals AG; Ferrer; Galenica S.A.; Teva Pharmaceuticals USA
  • Class Antipsychotics; Dibenzoxazepines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Agitation

Highest Development Phases

  • Marketed Agitation

Most Recent Events

  • 28 Apr 2017 Loxapine inhalation is no longer licensed to Medivir in Denmark, Finland, Norway, Iceland & Sweden
  • 31 Oct 2016 Ferrer completes a phase III trial for Agitation in Czech Republic, Spain and Germany (EudraCT2014-000456-29)
  • 10 Oct 2016 US FDA approves sNDA regarding certain changes in the product label and modifications to the Risk Evaluation Mitigation Strategy (REMS) Program for loxapine inhalation for Agitation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top